Peer reviewer for funding bodies including MRC, Wellcome, NW Cancer, Roy Castle , Leukaemia UK, Great Ormond Street
2018 - 2023
Professor David Allsup's Recognition (58)
COSMIC, a phase II randomised study investigating the efficacy of standard or high-dose ofatumumab in combination with chemotherapy in patients with relapsed chronic lymphocytic leukaemia
2017 - 2017
Description Poster presentation , International Workshop Chronic Lymphocytic Leukaemia
New YorkAffiliated Organisations Hull York Medical School
Local lead for delivery of 100,000 genome project
2016 - 2020
Description Local lead for the delivery of 100,000 genome project in Hull and East Yorkshire.
I oversaw recruitement of around 300 persons to this programmmeAffiliated Organisations Hull University Teaching Hospitals NHS Trust
New UKHCDO von Willebrand disease guidelines allow re-classification of a large proportion of adult patients and can result in de-diagnosis of patients without haemorrhagic consequences
2015 - 2015
Description Poster presentation British Society for Haematology Meeting Affiliated Organisations Hull York Medical School
Training in safe administration of intrathecal chemotherapy – is in situ simulation the answer?: A pilot study
2015 - 2015
Description BMJ Simulation & Technology Enhanced Learning Affiliated Organisations Hull York Medical School
Regional lead for intrathecal chemotherapy
2014 - 2024
Description Regional lead for intrathecal chemotherapy Affiliated Organisations Hull University Teaching Hospitals NHS Trust
Member of Trial Management Group FLAIR clinical trial
2013 - 2025
Description Member of Trial Management Group FLAIR clinical trial Affiliated Organisations Leeds Teaching Hospitals NHS Trust Projects STATIC: A Randomised Phase III Trial Comparing Continuous with Intermittent Treatment Strategies in Chronic Lymphocytic Leukaemia (CLL)
NCRI CLL clinical studies subgroup member
2010 - 2025
Description NCRI CLL clinical studies subgroup member Projects STATIC: A Randomised Phase III Trial Comparing Continuous with Intermittent Treatment Strategies in Chronic Lymphocytic Leukaemia (CLL)
Acted as an advisor to National Institue of Health and Care Excellence and European Medical Agency and NHS Choices.
2010 - 2024
Description Attended NICE and EMA workshops and advisory panels. Advised on the production of patient information by NHS Choices.
United Kingdom Chronic Lymphocytic Leukaemia Forum
2010 - 2025
Affiliated Organisations Hull York Medical School
UKHCDO
2005 - 2025
Description Member of United Kingdom Haemophilia Centre Directors Organisation.
FRCPath
2004 - 2025
Description Fellow Royal College of Pathologist
Member of haemato-oncology multidisciplinary team
2004 - 2030
Description Member of regional haemato-oncology MDT.
Chair of committee 2015-2023Affiliated Organisations Hull University Teaching Hospitals NHS Trust
Chair of Regional Haemostasis Multidisciplinary team
2004 - 2030
Description Chair of the regional haemostasis multidisciplinary team. Affiliated Organisations Hull University Teaching Hospitals NHS Trust
External Phd examiner.
2004 - 2023
Description Dr Allsup has acted as external examiner in six PhD vivas.
Educational Supervisor
2004 - 2030
Description Educational supervisor to multiple speciality trainees, internal medcine trainees and foundation doctors. Affiliated Organisations Hull University Teaching Hospitals NHS Trust
BSH
2000 - 2025
Description Member of British Society for Hematology
MRCP
1996 - 1996
Description MRCP